GenSight Biologics (GSGTF) Stock Price, News & Analysis

Company Overview

GenSight Biologics (OTCMKTS: GSGTF) is a clinical‐stage biopharmaceutical company specializing in the development of gene therapies for retinal and central nervous system diseases. The company leverages mitochondrial and optogenetic platforms to address unmet medical needs in vision loss and neurodegenerative conditions. Its pipeline focuses primarily on therapies designed to restore or preserve vision in patients suffering from Leber hereditary optic neuropathy (LHON) and age-related macular degeneration (AMD).

Founded in 2012 and headquartered in Paris, France, GenSight Biologics conducts research and clinical development across Europe and the United States. Its lead product candidate, LUMEVOQ, is an AAV‐based gene therapy intended to treat LHON caused by the ND4 mitochondrial DNA mutation. Additionally, GenSight is advancing GS030, an optogenetic therapy aimed at reactivating retinal cells in dry AMD patients. Both programs have progressed through early‐phase clinical trials, with ongoing studies evaluating safety, tolerability and visual function outcomes.

GenSight Biologics is led by Chief Executive Officer Bernard Gilly, who co‐founded the company to translate pioneering gene therapy science into potential treatments for blinding diseases. The management team combines expertise in ophthalmology, mitochondrial biology and clinical development, supporting collaborations with academic institutions and research hospitals. Through its dedicated vertically integrated R&D model, GenSight aims to bring first‐in‐class therapies to patients affected by inherited and degenerative eye disorders.

Key Stats

• Today's Range: $0.24 to $0.24
• 50-Day Range: $0.24 to $0.24
• 52-Week Range: $0.32 to $0.32
• Volume: N/A
• Average Volume: 583 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GSGTF Stock Analysis - Frequently Asked Questions

How have GSGTF shares performed this year?

GenSight Biologics' stock was trading at $0.24 at the start of the year. Since then, GSGTF shares have increased by 0.0% and is now trading at $0.24.

How do I buy shares of GenSight Biologics?

Shares of GSGTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 7/18/2025
• Next Earnings (Estimated): 9/19/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:GSGTF
• CIK: N/A
• Web: www.gensight-biologics.com
• Phone: (317) 621-7220
• Fax: N/A
• Employees: 16
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A